Mimotope vaccine efficacy gets a "boost" from native tumor antigens

Abstract

Tumor-associated antigen (TAA)-targeting mimotope peptides exert more prominent immunostimulatory functions than unmodified TAAs, with the caveat that some T-cell clones exhibit a relatively low affinity for TAAs. Combining mimotopebased vaccines with native TAAs in a prime-boost setting significantly improves antitumor immunity. © 2013 Landes Bioscience.